Developer of a multi-omics platform designed to detect cancer through a routine blood draw.
Developer of a multi-omics platform designed to detect cancer through a routine blood draw.
Decision/Risk Analysis📍 Brisbane, CAFounded 2014
Current Valuation
$2.2B
as of 2024-Q1
UNICORN
QL Price
$821.72M
-62% vs last round
QuantLogix's current estimate for Freenome, published 2026-09-09 — below the last disclosed round of $2.2B (2024-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$2.2B
2024-Q1
weight 0.18
Secondary market print
$434M
2026-06-27
weight 0.64
How this price has held up
No round has priced for Freenome since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-09 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Freenome, 2026-09-09 (2a16266c73ab2e52).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Freenome going public?
No. Freenome is private and has not filed to go public. There is no S-1 on file.
What is Freenome's valuation in 2026?
Freenome is valued at $2.2B as of 2024-Q1, set by its Later Stage VC ($254M, Feb 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Freenome filed an S-1?
No public S-1 is on file for Freenome.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2014
HQ
Brisbane, CA
Employees
392
Total Raised
$1.4B
Last Round
Later Stage VC — $254M (Feb 2024)
IPO Status
private
Fundraising Status
Later Stage VC · $254M · 2y 7mo ago
privateTotal raised $1.4B
Secondary Market
Implied price / share
$1.48
Last round price / share
$7.4
vs last round
-80.0%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Later Stage VC
$254M
Feb 2024
—
$2.2B
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
5
1 active · 1 recruiting
Focus areas
Adenoma
Cancer · Lung Cancer Diagnosis
Latest trial start
2023-11-28
Name-verified against lead sponsor "Freenome Holdings Inc." on ClinicalTrials.gov as of 2026-09-03. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▲ Hiring uptrend
44% of roles posted in last 30d
Open roles
27
via greenhouse
Product-build share
59%
engineering, research, product, design
Trajectory
expanding
product-led hiring — 59% of open roles build product; the rest are go-to-market and G&A.
No tracked executive churn; open roles trending up.
Counted from Freenome's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiotechnologyPersonal HealthHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q1. Refreshed quarterly.